InBody is a premier brand of body composition analyzers
that supports medical research and health diagnostics across
over 110 countries, driven by a robust network of international
subsidiaries and an average annual growth rate of 17%.
In the early 1990s, Dr. Kichul Cha, the founder and CEO, identified significant limitations and inaccuracies in the existing BIA devices, which were often unreliable for clinical use in patients requiring detailed body composition analysis. Leveraging his expertise in mechanical engineering, he embarked on designing a superior solution.
By 1996, Dr. Cha established InBody, and within two years, the inaugural InBody device was launched. Today, InBody has evolved from a modest biotech startup in South Korea into a global enterprise with branches and distributors across over 80 countries.
Our clientele rely on us to deliver precise, reliable, and clinically valuable body composition data, knowing well that InBody devices integrate ease of use with unmatched accuracy and consistency.
At InBody, we are dedicated to advancing patient care through precise measurement of muscle, fat, minerals, and water, enabling tailored health interventions and ongoing disease management. We continuously update our research database to foster collaboration and innovation, supporting clinicians and researchers in their pursuit of improved health outcomes.
At InBody BWA, our mission is to enhance lives by advancing the standard of care for critically ill patients. By leveraging our body water analysis technology, clinicians and researchers can achieve greater precision in patient care, ultimately improving outcomes and fostering better health.
To elevate patient health through precise measurement of muscle, fat, mineral, and water, advancing the standard of care by providing granular, non-invasive insights.
InBody was founded in South Korea. Products feature direct segmental multi-frequency bioelectrical impedance analysis (DSM-BIA) and an eight-point tactile electrode system to measure an individual’s body composition without the use of empirical data.
InBody established its first overseas subsidiary in Beverly Hills, California.
The second overseas subsidiary was established in Tokyo, Japan in this year as well.
InBody technology is FDA approved and results have been validated by research.
The InBody 570, capable of measuring segmental fat analysis including visceral fat level, is released.
The InBody 770, a new research-grade body composition analyser is launched and the InBody 570 wins the Red Dot Design Award.
iF DESIGN AWARD is given to the InBody 770.
InBody receives the 2015 Foreign Direct Investment Award from the Los Angeles Chamber of Commerce during World Trade Week.
InBody BAND and InLab win CES 2015 Innovation Award for wearable technologies.
InBody unveiled the InBody BAND, the world’s first wearable body composition device.
InBody expanded its business to global market.
In this year, InBody Europe, InBody Asia, InBody India were established.
Also, InBody launched cloud-based data software, LookinBody Web.
InBody Mexico was established.
InBody is contributing to the medical field in the global market through 7 overseas subsidiaries.
InBody released the InBody970 and BWA 2.0 – a new standard of innovation.
InBody BWA, Inc. was established In Pennsylvania to focus on the clinical care and research of chronic disease.
InBody introduced several innovative devices to enhance professional health measurements:
InBody580 and InBody380: Advanced, user-friendly body composition analyzers.
FRA Balance Measurement System: Designed to assess balance in senior populations at risk of frailty.
InGrip Digital Hand Dynamometer: A cutting-edge tool to evaluate grip strength, supporting frailty assessment in older adults.
For nearly 30 years, InBody has been on a mission to redefine health from its roots in Seoul, South Korea, to a global audience. Our guiding motto, “Make life better,” reflects our commitment to going beyond weight and BMI, helping people understand what truly matters: the composition of that weight. Fast forward to 2023, and our cloud app hit an incredible milestone of 100 million tests, proving that we’re making a real impact on lives worldwide.
Now, with InBodyBWA, we’re taking another transformative step for the brand. Our focus is on improving the standard of care for critically ill patients by leveraging the power of Body Water Analysis (BWA). This precision-driven approach allows for better, more personalized patient outcomes.
Partnering with the nation’s leading hospitals and universities, we’re not only addressing gaps in healthcare but also enhancing the quality of care patients receive. As we deepen long-standing relationships and forge exciting new ones, our dedicated team of experts from diverse medical and academic backgrounds is eager to bring InBodyBWA to more communities across the country.
Our mission is simple: share InBodyBWA, everywhere.
CEO
As a global enterprise, InBody is located in over 12 countries around the world with direct offices, and exports to about 110+ countries. Aside from the headquarters office, InBody Co., Ltd, located in South Korea, 11 subsidiaries and branches are located in USA, Netherland, Germany, UK, Mexico, China, Japan, India, Malaysia, Australia, and Vietnam.
InBody USA
InBodyBWA
InBody Mexico
InBody UK
InBody EU
InBody Germany
InBody India
InBody Asia
Biospace China
InBody Korea (HQ)
InBody Japan
InBody Oceania
InBody Vietnam
625, InBody Bldg., Eonju-ro, Gangnam-gu,
Seoul 06106, Korea
Mergenthalerallee 15 – 21, D-65760 Eschborn
11 Phoenix Park, Telford Way, Stephenson Industrial Estate, Coalville LE67 3HB, UK
Unit 2 82/86 Minnie St, Southport QLD 4215
Unit 3A-11 & 12, Oval Damansara, 685 Jalan Damansara, Kuala Lumpur, WP KL 60000, Malaysia
904, XingDiPlaza, No. 1698 YiShanRoad, Shanghai 201103, China
Unit No. G-B 10, Ground Floor, Art Guild House, L.B.S. Marg, Kurla (West), Phoenix Market City, Mumbai 400070, India
Tani Bldg., 1-28-6, Kameido, Koto-ku, Tokyo 136-0071, Japan